

Supplementary Table 1A.

Sensitivity and specificity of serum Nectin-4, CEA, and CYFRA 21-1 in detecting NSCLCs

	total	lung cancer patients n = 164	normal volunteers n = 131
Nectin-4			
serum Nectin-4 positive	91	88	3
serum Nectin-4 negative	204	76	128
		sensitivity 53.7%	specificity 97.7%
CEA			
serum CEA positive	73	70	3
serum CEA negative	222	94	128
		sensitivity 42.7%	specificity 97.7%
CYFRA 21-1			
serum CYFRA 21-1 positive	69	64	5
serum CYFRA 21-1 negative	226	100	126
		sensitivity 39.0%	specificity 96.2%

Supplementary Table 1B.

Association between serum Nectin-4-positivity and normal volunteers' characteristics (n = 131)

	Total n = 131	Serum Nectin-4 positive n = 3	Serum Nectin-4 absent n = 128	P-value: positive vs absent
Gender				
Male	88	2	86	>0.9999**
Female	43	1	42	
Age (years)				
< 65	116	2	114	0.3078**
≥ 65	15	1	14	
Smoking				
pack-years (±1SD)	16.4 ± 20.8	21.7 ± 33.3	16.3 ± 20.6	0.6589*
current smoker	36	1	35	0.6004**, **
former smoker	27	1	26	
never smoker	68	1	67	

**Fisher's exact test

*Mann-Whitney *U* test

**current & former vs never

Supplementary Table 1C.

Association between serum Nectin-4-positivity and COPD patients' characteristics (n=86)

	Total n = 86	Serum Nectin-4 positive n = 7	Serum Nectin-4 absent n = 79	P-value: positive vs absent
Gender				
Male	76	7	69	>0.9999**
Female	10	0	10	
Age (years)				
< 65	27	2	25	>0.9999**
>= 65	59	5	54	
Smoking				
pack-years (\pm 1SD)	66.7 \pm 44.4	69.3 \pm 60.0	66.5 \pm 43.2	0.8572 ⁺
current smoker	16	1	15	>0.9999**
former smoker	70	6	64	
Respiratory function (\pm1SD)				
FEV 1.0 (l)	1409.4 \pm 576.7	1486.7 \pm 597.2	1433.9 \pm 589.3	0.8341 ⁺
FEV 1 / FVC %	52.7 \pm 15.2	56.6 \pm 12.1	51.4 \pm 13.8	0.383 ⁺
FEV 1 (% pred)	46.9 \pm 19.2	47.6 \pm 19.4	46.6 \pm 18.3	0.8879 ⁺

**Fisher's exact test,

⁺Mann-Whitney U test

Supplementary Table 2A.

Cox's proportional hazards model analysis of prognostic factors in early NSCLC (Stage I) patients treated with surgery

Variables	Hazards ratio	95% CI	Unfavorable/Favorable	P-value
Univariate analysis				
Serum Nectin-4	3.209	1.119-9.203	positive / negative	0.0301*
Age (years)	1.486	0.466-4.738	>=65 / < 65	0.5033
Gender	1.360	0.472-3.922	Male / Female	0.5688
Histological type	1.144	0.256-5.118	ADC / non-ADC	0.8602
pT factor	1.092	0.366-3.258	T2 / T1	0.8751
Smoking	1.388	0.481-4.011	smoker/non-smoker	0.3689

ADC, adenocarcinoma, *P < 0.05

Supplementary Table 2B.

Cox's proportional hazards model analysis of prognostic factors in advanced NSCLC (Stage IIIB-IV) patients treated with chemotherapy

Variables	Hazards ratio	95% CI	Unfavorable/Favorable	P-value
Univariate analysis				
Serum Nectin-4	3.145	1.078-9.176	positive / negative	0.0360*
Age (years)	1.167	0.527-2.585	>=65 / < 65	0.7026
Gender	1.090	0.454-2.613	Male / Female	0.8475
Histological type	2.026	0.794-5.170	non-ADC / ADC	0.1395
Performance status	15.852	3.467-72.488	PS 2/ PS 0-1	0.0004*
Stage	2.836	0.848-9.488	IV / IIIB	0.0906
Smoking	1.147	0.493-2.669	smoker/non-smoker	0.7497
Multivariate analysis				
Nectin-4	3.139	1.074-9.173	Serum Nectin-4 (+) / (-)	0.0394*
Performance status	15.765	1.074-72.173	PS 2/ PS 0-1	0.0004*

ADC, adenocarcinoma, *P < 0.05